Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 1766 results for patient safety

  1. NICE encourages further research into transcranial direct current stimulation (tDCS) for depression, which should document how patients were selected and any other treatments they were having. It should describe the precise method and regime used for administering tDCS. Outcome measures should include the duration of effect. NICE may update the guidance on publication of further evidence.

    direct current stimulation (tDCS) for depression, which should document how patients were selected and any other treatments they were...

    Research recommendation
    Published
    12 October 2015

  2. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    Recommendation ID NG191/3 Question What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs)...

    Research recommendation
    Published
    10 August 2021

  3. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    Recommendation ID NG191/2 Question What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE)...

    Research recommendation
    Published
    10 August 2021

  4. Long-term effects of IVF with or without intracytoplasmic sperm injection in children:- What are the long-term (over 20 years) effects of IVF with or without intracytoplasmic sperm injection (ICSI) in children in the UK?

    topic is important in informing patients, service providers and society at large about the potential long-term safety of...

    Research recommendation
    Published
    9 June 2015

  5. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  6. Access to medicines:- Does the use of directly observed supply of named high-risk medicines (that is, not supplying the medicines to people to hold in-possession), reduce diversion, abuse and non-adherence?

    observed administration is reserved for high-risk medicines and vulnerable patients. But different medicines are categorised as high...

    Research recommendation
    Published
    10 February 2017

  7. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Recommendation ID NG191/1 Question What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological...

    Research recommendation
    Published
    10 August 2021

  8. What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH?

    Question What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH? Any explanatory

    Research recommendation
    Published
    15 November 2019

  9. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued Reference number: GID-TA10105

    Technology appraisal guidance
    Discontinued

  10. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development Reference number: GID-TA11351 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  12. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

    NICE guideline
    Published
    30 June 2017
    View recommendations

    Sections for NG70

  13. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  14. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA896